Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
05 2023
Historique:
received: 26 04 2022
revised: 31 05 2022
accepted: 25 06 2022
medline: 25 4 2023
pubmed: 9 8 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

Alcohol is one of the leading causes of hepatocellular carcinoma (HCC). However, pooled estimates of HCC incidence in alcohol-associated cirrhosis have not been evaluated systematically. We performed a pooled analysis of time-to-event data to provide robust estimates for the incidence of HCC in alcohol-associated cirrhosis. Medline, Embase, Cochrane Central Register, Scopus, and Web of Science were searched from inception to August 2021. Individual patient data were reconstructed from published Kaplan-Meier curves, and a pooled analysis of cumulative HCC incidence was performed using a random-effects model. We screened 5022 articles and included 18 studies (148,333 patients). In the pooled analysis, the cumulative incidence of HCC in alcohol-associated cirrhosis at 1, 5, and 10 years among studies that accounted for the competing risk of death without HCC was 1%, 3%, and 9%, respectively. A secondary analysis by traditional meta-analysis determined that the HCC incidence rate was higher in cohorts enrolled in a HCC surveillance program (18.6 vs 4.8 per 1000 person-years; P = .001) vs those who were not enrolled in a surveillance program. Meta-regression showed that diabetes, smoking, variceal bleeding, and hepatic decompensation were associated with a higher risk of HCC. Our analysis determined that the 5- and 10- year cumulative risk of HCC in alcohol-associated cirrhosis was 3% and 9%, respectively, with a higher incidence in cohorts that were enrolled in a HCC surveillance program. These data should be validated further in large prospective studies, and may have important implications for HCC screening and surveillance among patients with alcohol-associated cirrhosis.

Sections du résumé

BACKGROUND & AIMS
Alcohol is one of the leading causes of hepatocellular carcinoma (HCC). However, pooled estimates of HCC incidence in alcohol-associated cirrhosis have not been evaluated systematically. We performed a pooled analysis of time-to-event data to provide robust estimates for the incidence of HCC in alcohol-associated cirrhosis.
METHODS
Medline, Embase, Cochrane Central Register, Scopus, and Web of Science were searched from inception to August 2021. Individual patient data were reconstructed from published Kaplan-Meier curves, and a pooled analysis of cumulative HCC incidence was performed using a random-effects model.
RESULTS
We screened 5022 articles and included 18 studies (148,333 patients). In the pooled analysis, the cumulative incidence of HCC in alcohol-associated cirrhosis at 1, 5, and 10 years among studies that accounted for the competing risk of death without HCC was 1%, 3%, and 9%, respectively. A secondary analysis by traditional meta-analysis determined that the HCC incidence rate was higher in cohorts enrolled in a HCC surveillance program (18.6 vs 4.8 per 1000 person-years; P = .001) vs those who were not enrolled in a surveillance program. Meta-regression showed that diabetes, smoking, variceal bleeding, and hepatic decompensation were associated with a higher risk of HCC.
CONCLUSIONS
Our analysis determined that the 5- and 10- year cumulative risk of HCC in alcohol-associated cirrhosis was 3% and 9%, respectively, with a higher incidence in cohorts that were enrolled in a HCC surveillance program. These data should be validated further in large prospective studies, and may have important implications for HCC screening and surveillance among patients with alcohol-associated cirrhosis.

Identifiants

pubmed: 35940513
pii: S1542-3565(22)00727-3
doi: 10.1016/j.cgh.2022.06.032
pii:
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article Review Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1169-1177

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK120515
Pays : United States
Organisme : NIEHS NIH HHS
ID : P42 ES010337
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001442
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL147835
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121378
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA029019
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK130190
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK124318
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK106419
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK061734
Pays : United States

Informations de copyright

Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Daniel Q Huang (DQ)

NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore. Electronic address: daniel_huang@nus.edu.sg.

Darren J H Tan (DJH)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Cheng Han Ng (CH)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Maral Amangurbanova (M)

NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California.

Nancy Sutter (N)

NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California.

Phoebe Wen Lin Tay (PW)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Wen Hui Lim (WH)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Jie Ning Yong (JN)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Ansel Tang (A)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Nicholas Syn (N)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Mark D Muthiah (MD)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.

Eunice X X Tan (EXX)

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.

Shravan Dave (S)

NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California.

Benjamin Tay (B)

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.

Abdul M Majzoub (AM)

Division of Internal Medicine, Conemaugh Memorial Medical Center, Johnstown, Pennsylvania.

Danielle Gerberi (D)

Mayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota.

Beom Kyung Kim (BK)

NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.

Rohit Loomba (R)

NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California. Electronic address: roloomba@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH